KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $32.00 price target on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright reaffirmed a buy rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday. Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a strong-buy rating in a research report on Monday, August 26th.

KalVista Pharmaceuticals Trading Down 4.1 %

Shares of NASDAQ KALV opened at $12.34 on Friday. KalVista Pharmaceuticals has a 12-month low of $7.21 and a 12-month high of $16.88. The company has a market cap of $520.60 million, a price-to-earnings ratio of -3.63 and a beta of 0.91. The stock’s 50 day simple moving average is $13.17 and its 200 day simple moving average is $12.42.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. As a group, equities analysts forecast that KalVista Pharmaceuticals will post -3.57 earnings per share for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the completion of the transaction, the insider now directly owns 84,467 shares of the company’s stock, valued at approximately $1,014,448.67. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,452 shares of company stock valued at $282,491. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Capital World Investors acquired a new position in KalVista Pharmaceuticals in the first quarter worth approximately $17,370,000. Great Point Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the 2nd quarter worth $15,768,000. StemPoint Capital LP raised its position in shares of KalVista Pharmaceuticals by 174.4% during the first quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock worth $13,770,000 after purchasing an additional 737,886 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in shares of KalVista Pharmaceuticals by 11.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock valued at $44,373,000 after purchasing an additional 383,435 shares during the last quarter. Finally, Zimmer Partners LP acquired a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at $830,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.